“Safe use of Interleukin-17 Inhibitors for Psoriasis and Psoriatic Arthritis in Two Patients with a History of Lymphoproliferative Disease” (2020) SKIN The Journal of Cutaneous Medicine, 4(3), pp. 256–259. doi:10.25251/skin.4.3.7.